So far, the search for a cure for Alzheimer Disease (AD) has been unsuccessful. The only
approved drugs attenuate some symptoms, but do not halt the progress of this disease …

Exosome-based drug delivery is emerging as a promising field with the potential to
revolutionize therapeutic interventions. Exosomes, which are small extracellular vesicles …

Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

The prevalence of Alzheimer's disease (AD) continues to rise due to the increasing aging
population. Among the various genetic factors associated with AD, apolipoprotein E (ApoE) …

Alzheimer's disease (AD) is a progressive neurological disorder that affects the central
nervous system (CNS), leading to memory and cognitive decline. In AD, the brain …

Alzheimer disease (AD) is a common neurodegenerative disease with a late onset. It is
critical to identify novel blood-based DNA methylation biomarkers to better understand the …

Alzheimer's disease (AD) is the main neurodegenerative disorder characterized by several
pathophysiological features, including the misfolding of the tau protein and the amyloid beta …

Alzheimer's disease (AD) is a progressive degenerative neurological illness with insidious
onset. Due to the complexity of the pathogenesis of AD and different pathological changes …

This review provides a comprehensive examination of the role of clathrin-mediated
endocytosis (CME) in Alzheimer's disease (AD) pathogenesis, emphasizing its impact …

Helicobacter pylori infection consists a high global burden affecting more than 50% of the
world's population. It is implicated, beyond substantiated local gastric pathologies, ie, peptic …